CoChat

TERT promoter mutations in melanoma survival

Open access
Nagore, Eduardo, Heidenreich, Barbara, Rachakonda, Sívaramakrishna, Garcia‐Casado, Zaida, Requena, Celia, Soriano, Virtudes, Frank, Christoph, Traves, Victor, Quecedo, Esther, Sanjuan‐Gimenez, Josefa, Hemminki, Kari, Landi, Maria Teresa, Kumar, Rajiv · 2016 · International Journal of Cancer
Cited by 119

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Despite advances in targeted therapies, the treatment of advanced melanoma remains an exercise in disease management, hence a need for biomarkers for identification of at‐risk primary melanoma patients. In this study, we aimed to assess the prognostic value of TERT promoter mutations in primary melanomas. Tumors from 300 patients with stage I/II melanoma were sequenced for TERT promoter and BRAF/NRAS mutations. Cumulative curves were drawn for patients with and without mutations with progression‐free and melanoma‐specific survival as outcomes. Cox proportional hazard regression models were used to determine the effect of the mutations on survivals. Individually, presence of TERT promoter and BRAF/NRAS mutations associated with poor disease‐free and melanoma‐specific survival with modification of the effect by the rs2853669 polymorphism within the TERT promoter. Hazard ratio (HR) for simultaneous occurrence of TERT promoter and BRAF/NRAS mutations for disease‐free survival was 2.3 (95% CI 1.2–4.4) and for melanoma‐specific survival 5.8 (95% CI 1.9–18.3). The effect of the mutations on melanoma‐specific survival in noncarriers of variant allele of the polymorphism was significant (HR 4.5, 95% CI 1.4–15.2) but could not be calculated for the carriers due to low number of events. The variant allele per se showed association with increased survival (HR 0.3, 95% CI 0.1–0.9). The data in this study provide preliminary evidence that TERT promoter mutations in combination with BRAF/NRAS mutations can be used to identify patients at risk of aggressive disease and the possibility of refinement of the classification with inclusion of the rs2853669 polymorphism within TERT promoter.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.30042

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 119

Metadata

Authors
Nagore, E., Heidenreich, B., Rachakonda, S., Garcia‐Casado, Z., Requena, C., Soriano, V., Frank, C., Traves, V., Quecedo, E., Sanjuan‐Gimenez, J., Hemminki, K., Landi, M. T., & Kumar, R.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2016-03-02
Volume
139
Issue
1
Pages
75-84
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2261233232
Cited by
119
References
12
FWCI
8.13
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TERT promoter mutations in melanoma survival. https://app.cochat.ai/papers/10.1002/ijc.30042
The paper
Nagore, E., Heidenreich, B., Rachakonda, S., Garcia‐Casado, Z., Requena, C., Soriano, V., Frank, C., Traves, V., Quecedo, E., Sanjuan‐Gimenez, J., Hemminki, K., Landi, M. T., & Kumar, R. (2016). TERT promoter mutations in melanoma survival. International Journal of Cancer. https://doi.org/10.1002/ijc.30042

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.